Geneva, Switzerland, April 6, 2022-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, ...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 8, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage ...
The transient receptor potential vanilloid (TRPV1) ion channel is a polymodal nociceptor broadly expressed in sensory neurons involved in pain sensation, thereby playing an essential role in analgesia ...
Geneva, Switzerland, June 22, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...
Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...
Vanderbilt University has synthesized metabotropic glutamate (mGlu2) receptor negative allosteric modulators reported to be useful for the treatment of depression, anxiety, Alzheimer's disease, autism ...
Please provide your email address to receive an email when new articles are posted on . A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and ...
Boehringer Ingelheim Pharma GmbH & Co. KG has disclosed dioxane derivatives acting as mGluR4 negative allosteric modulators reported to be useful for the treatment of neurodegeneration, metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results